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Abstract
Background: The carnitine precursor trimethyllysine (TML) is associated with progression 
of atherosclerosis, possibly through a relationship with trimethylamine-N-oxide (TMAO). 
Riboflavin is a cofactor in TMAO synthesis. We examined prospective relationships of 
circulating TML and TMAO with acute myocardial infarction (AMI) and potential effect 
modifications by riboflavin status.  
Methods: By Cox modelling, risk associations were examined among 4098 patients (71.8% 
men) with suspected stable angina pectoris. Subgroup analyses were performed according to 
median plasma riboflavin.
Results: During a median follow-up of 4.9 years, 336 (8.2%) patients experienced an AMI. 
The age- and sex-adjusted hazard ratio (HR) (95% CI) comparing the 4th vs. 1st TML quartile 
was 2.19 (1.56–3.09). Multivariable adjustment for traditional cardiovascular risk factors and 
indices of renal function only slightly attenuated the risk estimates (HR [95% CI] 1.79 [1.23-
2.59]), which were particularly strong among patients with riboflavin levels above the median 
(pint=0.035). Plasma TML and TMAO were strongly correlated (rs=0.41; p<0.001); however, 
plasma TMAO was not associated with AMI risk in adjusted analyses (HR [95% CI] 0.81 
[0.58-1.14]). No interaction between TML and TMAO was observed. 
Conclusion: Among patients with suspected stable angina pectoris, plasma TML, but not 
TMAO, independently predicted risk of AMI. Our results motivate further research on 
metabolic processes determining TML levels and their potential associations with 
cardiovascular disease. We did not adjust for multiple comparisons, and the subgroup-
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eGFR: Estimated glomerular filtration rate
FMO3: Flavin-containing monooxygenase 3
NRI: Net reclassification improvement
TMAO: Trimethylamine-N-oxide
TML: Trimethyllysine
WECAC: Western Norway Coronary Angiography Cohort
WENBIT: Western Norway B-Vitamin Intervention Trial
γBB: γ-butyrobetaine
Introduction
Increasing evidence suggests that the gut microbiota contributes to atherosclerosis through 
metabolism of dietary components [1]. In particular, trimethylamine-N-oxide (TMAO) has 
gained attention as a metabolite potentially linking intestinal bacteria to cardiovascular 
disease (CVD) [2]. TMAO is a product of the hepatic oxidation of trimethylamine (TMA) by 
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generated by the gut microbiota-dependent metabolism of dietary quaternary ammoniums 
containing a TMA moiety, such as choline, γ-butyrobetaine (γBB) and carnitine [4]. 
Numerous observational studies have reported associations between circulating TMAO and 
future cardiovascular risk and mortality [5]; however, several controversies exist regarding 
the potential causal role of TMAO in CVD [6-8]. 
The methylated amino acid trimethyllysine (TML) can serve as a TMAO-precursor 
[9], and has been associated with progression of atherosclerosis [10]. TML is introduced by a 
variety of plant- and animal-derived dietary sources [9, 11]. Further, TML is generated 
endogenously by posttranslational methylation of lysine residues in proteins, such as histones, 
a process considered central in epigenetic regulation of gene transcription [12]. TML is a 
precursor for the endogenous production of carnitine, with γBB as an intermediate, and TML 
availability regulates the rate of carnitine biosynthesis [13], essential for the transport of fatty 
acids over the mitochondrial membrane for their subsequent β-oxidation. Despite the 
involvement of TML in multiple distinct pathways potentially associated with atherogenesis 
[14], data examining relationships between circulating TML and CVD endpoints are scarce. 
Notably, in an untargeted metabolomics study [9], TML was strongly related to adverse 
cardiovascular prognosis, a finding very recently replicated among patients presenting with 
acute coronary syndrome [15].
In this study of more than 4000 patients with suspected stable coronary heart disease, 
we evaluated circulating TML and TMAO in relation to future acute myocardial infarction 
(AMI). As TMAO is produced using riboflavin as a cofactor, we also examined potential 
effect modifications by circulating riboflavin. 
Material and Methods
Study population
The Western Norway Coronary Angiography Cohort (WECAC) includes patients with 
suspected stable angina pectoris (SAP), and has been described in detail previously [16]. In 
short, 4164 patients underwent elective coronary angiography either at Haukeland University 
Hospital (n=3413) or at Stavanger University Hospital (n=751), Norway, during 2000 to 
2004. A total of 2573 (61.8%) of the patients were enrolled in the Western Norway B-
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randomized secondary prevention trial with B-vitamin treatment [17]. Patients not enrolled in 
WENBIT did not receive any study intervention.
The present study excluded 66 patients due to missing baseline data on circulating 
TML, γBB, TMAO or riboflavin, leaving 4098 patients eligible for the final analyses.
Baseline characteristics and biochemical analyses
The collection of baseline data and biochemical analyses has been described previously [18, 
19]. Information on patients’ lifestyle and medical history was obtained from self-
administered questionnaires and verified by comparing to hospital records when available.
For patients admitted to Haukeland University Hospital, venous blood samples were 
drawn at baseline, usually 1-3 days before coronary angiography. At Stavanger University 
Hospital, samples were drawn immediately after the procedure. Routine laboratory analyses 
were performed at hospital laboratories at Haukeland University Hospital or Stavanger 
University Hospital. For study-specific analyses, serum and plasma were immediately 
prepared and stored in 2 mL Vacutainer tubes (Becton, Dickinson and Company, United 
States) at -80 ̊C until thawed and analyzed by laboratory staff, blinded to the clinical outcome 
of the patients. Plasma TML, plasma TMAO, serum γBB and plasma riboflavin were 
measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) [20, 21]. 
Clinical endpoints
The primary endpoint of the present study was new fatal or nonfatal AMI, classified in 
accordance with the International Statistical Classification of Disease Tenth Revision codes 
I21, I22, I46.1, R96 and R98. Events occurring within 24 hours after coronary artery bypass 
grafting or percutaneous coronary intervention were considered procedure-related and were 
excluded. Information on events was obtained from the Cause of Death registry at Statistics 
Norway (http://www.ssb.no) and the Western Norway Cardiovascular Registry [22]. Study 
endpoints were assigned by an independent endpoint committee. Two independent clinicians 
adjudicated the final diagnosis. Any disagreements were resolved by a third adjudicator. 
Patients were followed until December 31st, 2006. 
Ethics statements
The study protocol was in accordance with the Declaration of Helsinki, and was approved by 
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Norwegian Medicines Agency, and the Norwegian Data Inspectorate. All patients provided 
written informed consent.
Statistical analyses
Continuous variables are presented as medians (25th-75th percentiles) and categorical variables 
are presented as counts (%). Patients baseline characteristics were assessed over TML 
quartiles, trends over quartiles were tested by logistic regression for dichotomous and ordinal 
variables and by linear regression for continuous variables. Baseline associations were 
evaluated using age- and sex-adjusted Spearman rho correlation coefficients.
Event-free survival was estimated using crude Kaplan-Meier curves and differences in 
survival across TML quartiles were assessed with the log-rank test. Cox-regression analyses 
in univariate, age- and sex-adjusted (Model 1) and multivariable adjusted (Model 2; adjusted 
for age, sex, diabetes mellitus, current smoking, hypertension, estimated glomerular filtration 
rate [eGFR],  apolipoprotein [apo] B100 and apoA1) models were used to obtain hazard ratios 
(HRs) and 95% confidence intervals (CIs).
Results are reported according to the 4th vs. 1st quartile and per 1 standard deviation 
(SD) increment of log transformed concentrations of plasma metabolites. Effect modifications 
according to riboflavin and TMAO levels, in addition to parameters included in the Cox 
model 2, were tested by introducing interaction terms to the Cox model 1. Also, we assessed 
the TML-AMI risk association according to left ventricular ejection fraction (LVEF).
The possible influence of unmeasured factors was evaluated by introducing E-value to 
the Cox model 2, as per recent recommendations of sensitivity analysis in observational 
studies [23]. Further, model performance of the Cox Model 2 with and without log-
transformed standardized plasma TML was assessed. We tested the difference in C-statistics 
using Delong´s test [24] in 500 stratified 10-fold cross-validations, and calculated the net 
reclassification improvement (1/2NRI>0) [25, 26].
Since the nature of our research analysis was hypothesis-testing, we did not adjust for 
multiple comparisons [27] and the two-tailed significance level was set to 0.05 for all 
statistical models. All statistical tests were performed using SPSS for Windows (version 23; 
SPSS IBM, NY, USA) and R version 3.3.0 (packages “survival” [v3.1-8], pROC [v1.16.1] 
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Baseline characteristics of the study population according to quartiles of plasma TML are 
presented in Table 1. The current cohort consisted of 71.8% men, median (25th-75th 
percentile) age at inclusion was 62 (55-70) years. Median (25th-75th percentile) plasma levels 
of TML were 0.67 (0.54-0.87) µmol/L. There was a positive relationship between incremental 
TML quartiles and age and BMI, whereas a negative association was observed with eGFR 
and serum HDL cholesterol. A higher proportion of patients in the upper TML quartiles had 
hypertension and a lower proportion were smokers. Plasma TML was not associated with 
baseline statin prescription status.
As presented in Table 2, plasma TML was positively correlated with TMAO as well as 
downstream metabolites in the carnitine biosynthesis. The strongest associations with plasma 
TML were observed for γBB (rs=0.41, p<0.001) and TMAO (rs=0.41, p<0.001).
Predictors of subsequent AMI
During median (25th-75th percentile) follow up of 4.9 (3.6-6.0) years, 336 (8.2%) patients 
were registered with an AMI. Figure 1 shows increased risk of AMI with increasing TML 
quartiles (plog-rank<0.001). Univariate and multivariable HRs (95% CI) for AMI comparing the 
4th vs. 1st quartile of TML were 2.73 (1.97-3.79; p<0.001) and 1.79 (1.23-2.59; p=0.002), 
respectively (Table 3).
As we observed moderate to strong correlations between plasma TML and circulating 
γBB, carnitine and TMAO, we also evaluated whether additional adjustment for these 
biomarkers influenced the TML-AMI risk association. However, including any of the 
biomarkers either separately (data not shown) or combined in Cox model 2 only marginally 
affected the results (HR [95% CI] for AMI comparing the 4th vs. 1st quartile of TML 1.85 
[1.27-2.69].
Similarly, addition of the combination of prior AMI, prior percutaneous coronary 
intervention, prior coronary artery bypass grafting, and peripheral artery disease did not 
substantially alter the risk estimates (HR [95% CI] for AMI comparing the 4th vs. 1st quartile 
of TML 1.60 [1.10-2.32; p=0.014]). Adjustment for statin prescription status at discharge or 










This article is protected by copyright. All rights reserved
Both TMAO and γBB showed positive relationships with AMI in crude analyses 
(Table 4 and Table S1). However, these associations were completely attenuated in adjusted 
Cox models 1 and 2. 
Possible effect modifiers
The risk of AMI per 1-SD increment of log-transformed TML was particularly strong in 
patients with plasma riboflavin above the median (pint=0.035); otherwise, no statistically 
significant effect modifications were observed (Table 5). As shown in Table S2, plasma TML 
was predictive of AMI in both patients with LVEF<40% and LVEF≥40%.
Plasma riboflavin also modified the TMAO-AMI risk association (pint=0.010), with 
stronger associations observed in the high-riboflavin group (Table S3). There were no effect 
modifications by levels of riboflavin on the AMI risk associated with γBB (data not shown).
Sensitivity analysis, model discrimination and reclassification
Application of E-value formula to the Cox model 2 revealed good strength of the observed 
association between plasma TML and AMI, with E-values of 2.69 and 1.54 for the effect 
estimate and the lower reported CI, respectively, when comparing the 4th vs. 1st TML quartile.
After exclusion of patients receiving B-vitamin treatment in WENBIT (n=1891), we 
obtained numerically stronger relationships between plasma TML and risk of AMI (Table 
S4); however, there were no statistically significant interactions according to study 
intervention (Pint≥0.43) (Table S5).
The addition of plasma TML as a covariate to Cox model 2 resulted in borderline 
significant improvements in patient reclassification (1/2NRI >0 [95% CI]: 0.074 [-0.006-
0.136, p=0.067], whereas the C-statistic did not significantly improve (AUC 0.690 [with 
TML] vs. 0.685 [without TML], p=0.48).
Discussion
Principal findings
This large, prospective cohort of patients with suspected stable coronary heart disease showed 
that higher circulating TML was associated with increased risk of experiencing an AMI, also 
after adjustment for traditional risk factors, indices of renal function and plasma TMAO. 
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riboflavin. TML levels were strongly related to plasma TMAO and serum γBB; however, 
neither of the latter two biomarkers added predictive value in adjusted analyses. 
TML and CVD events in previous epidemiologic studies
We previously showed that higher levels of TML were associated with progression of 
atherosclerosis in a sub-cohort from the current source population who underwent repeat 
coronary angiography [10]. In a small study among patients with carotid atherosclerosis [28], 
circulating TML was predictive of cardiovascular death. More recently, an untargeted 
metabolomics study [9] identified TML as a predictor of future major adverse cardiovascular 
events among 2140 subjects with comparable follow-up time as the present cohort, a finding 
subsequently validated in a multi-center study evaluating patients presenting with acute 
coronary syndrome [15]. The present cohort extends the association between plasma TML 
and CVD by identifying TML as a strong independent risk marker for AMI in patients with 
suspected stable coronary heart disease.
TML and TMAO 
In agreement with two recent reports [9, 15], we observed a strong correlation between 
circulating levels of plasma TML and TMAO at baseline. TML is converted to the TMAO-
precursor TMA in a gut microbiota-dependent fashion in mouse and human fecal cultures; 
however, the overall TMA-generation appears to be relatively low [9]. Accordingly, dietary 
TML has not shown to increase circulating TMAO in mouse models [9]. In the current study, 
TMAO did not attenuate the TML-AMI-relationship when included in the multivariable 
model, nor did we observe any effect modification according to TMAO levels. Thus, the 
observed relationship between TML and AMI seems to reflect biological mechanisms at least 
partly independent of TMAO. 
Surprisingly, plasma TMAO did not add any prognostic value in this cohort. Although 
the majority of experimental [2] and epidemiological [5] evidence has implicated TMAO in 
CVD development, whether reducing circulating TMAO actually improves CVD prognosis is 
not known. Indeed, TMAO is related to several potentially confounding proatherogenic 
conditions [8, 29], and may also exert protective functions [6, 30]. Further, a large meta-
analysis [31] did not support an association of the dietary TMAO-precursors choline and 
betaine with incident CVD. Notably, our findings from a Norwegian population are in line 
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weaker relationships between TMAO and adverse prognosis in northern/western European 
populations compared to other European regions. The present results also support a recent 
study among high-risk individuals with type 2-diabetes [33], in which TMAO showed no 
predictive value for incident CVD events.
TML, carnitine biosynthesis and renal function
TML has previously mainly been evaluated for its role as a precursor for endogenous 
carnitine biosynthesis and hence its importance for the β-oxidation of fatty acids [13]. 
Impairments in carnitine homeostasis is considered an important contributor to CVD, likely 
through development of endothelial dysfunction [34]. As expected, circulating TML 
correlated with both downstream metabolites γBB and carnitine. γBB has shown 
proatherogenic properties in rodent models [35] and has been related to cardiovascular death 
in a smaller study among patients with carotid atherosclerosis [28]; however, the authors did 
not adjust for traditional CVD risk factors. To our knowledge, our study is the first to evaluate 
circulating γBB in relation to AMI, but similar to TMAO, γBB was not predictive of AMI risk 
once adjusted for potential confounders. 
Notably, we recently demonstrated TML and γBB to be oppositely related to risk of 
incident type 2 diabetes, possibly indicating an impaired conversion of TML to γBB among 
subjects prone to diabetes development [21]. Potentially, similar impairments in carnitine 
biosynthesis could underlie the TML-AMI-relationship observed in the present work, 
although adjusting for diabetes at baseline did not attenuate the risk association. Importantly, 
however, circulating γBB concentrations also depend on gut microbiota-dependent 
mechanisms [35], and thus partly reflects pathways independent of TML.
TML clearance depends on renal function [13]; accordingly, we observed an inverse 
correlation between plasma TML and eGFR at baseline. Interestingly, although not 
statistically significant, the TML-AMI relationship was predominately present in patients with 
eGFR below the median. However, including eGFR in Model 2 did not substantially alter the 
risk estimates, suggesting additional mechanisms than impaired renal function underlying the 
increased AMI-risk. As most subjects in the present study had adequate renal function, future 
studies among patients with renal impairment are needed to further evaluate potential 
interactions between circulating TML, kidney disease and CVD. 
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In histones, lysine is one of only two amino acids that can be methylated, i.e. forming TML, 
methyllysine and dimethyllysine. Methyl groups for this post-translational modification are 
provided by S-adenosyl methionine [36], generated by one-carbon metabolism. Hence, 
elevated circulating TML could reflect a disturbance in histone methylation due to changes in 
methylation potential, shown to be associated with CVD, probably due to an influence on the 
expression of genes associated with atherogenesis [12].
The effect modification by circulating riboflavin on the risk association between TML 
and AMI could potentially be due to increased TMAO production caused by upregulation of 
FMO3-activity when riboflavin levels are elevated. However, as TMAO did not 
independently predict risk of AMI, the effect modification by riboflavin is likely due to other 
mechanisms. Importantly, FMO3 itself is shown to have proatherogenic properties 
independent of TMAO [3, 37]. In addition, several enzymes in the one-carbon metabolism 
important for regulation of methylation potential [38] are riboflavin dependent, including 
methylene tetrahydrofolate reductase and methionine synthase reductase. Hence, the 
association between elevated TML and AMI might reflect altered flux through one or more of 
these enzymes when riboflavin is elevated. Indeed, future studies evaluating potential 
interactions between one-carbon metabolites and circulating TML could provide further 
insight into metabolic mechanisms relating TML to CVD. 
Strengths and limitations
Major strengths of the study include the large population size, the detailed information on 
baseline clinical and biochemical characteristics, and the long-term follow-up with endpoint 
data collected from a patient-administrative and a population-based registry. We cannot rule 
out underreporting of clinical features or diseases at baseline, or of clinical end points. As in 
any observational study, residual confounding might influence the assessment of risk 
predictors. However, we observed high E-values of the association between TML and AMI, 
which reduces the potential of bias from unobserved factors and unmeasured cofounders [23]. 
We mainly studied white men with stable coronary heart disease, and our results may not be 
applicable to populations with other demographic characteristics. Lastly, we did not adjust for 
multiple comparisons, which increases the risk of type 1 statistical errors.
Conclusion
Elevated circulating TML was associated with increased risk of AMI in patients with 
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indices of renal function, HbA1c and TMAO. TML strongly correlated with its downstream 
metabolite γBB and TMAO; however, neither γBB nor TMAO were independent risk markers 
of AMI. Future studies should aim to examine metabolic processes determining circulating 
levels of TML and their potential associations with CVD risks. We did not adjust for multiple 
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Figure legends
Figure 1. Kaplan–Meier curve showing crude event-free survival according to quartiles of 











This article is protected by copyright. All rights reserved
Table 1. Baseline characteristics of the total study cohort (n=4098) according to quartiles of plasma trimethyllysine














Plasma TML, µmol/L 0.5 (0.4-0.5) 0.6 (0.6-0.6) 0.8 (0.7-0.8) 1.1 (0.9-1.3) …
 Age, y 60 (53-67) 62 (55-69) 63 (55-70) 64 (56-72) <0.001
 Male sex, n (%) 534 (52.6) 702 (69.3) 867 (81.3) 840 (83.7) <0.001
 BMI 25 (23-28) 26 (24-28) 26 (24-29) 26 (24-29) <0.001
 Coronary risk factor, n (%)  
 Hypertension 420 (41.4) 447 (44.1) 489 (45.9) 558 (55.6) <0.001
 Diabetes mellitus 123 (12.1) 107 (10.6) 121 (11.4) 129 (12.8) 0.52
 Current smoking 354 (34.9) 333 (32.9) 310 (29.1) 304 (30.3) 0.02
HbA1c* 6.3 (5.6-7.2) 6.2 (5.6-6.9) 6.2 (5.5-6.9) 6.0 (5.3-6.7) <0.001
eGFR, mL/min per 1.73m2 97 (88-104) 92 (83-99) 88 (78-97) 82 (65-95) <0.001
Serum CRP, mg/L 1.7 (0.8-4.4) 1.7 (0.8-3.4) 1.9 (0.9-3.8) 1.9 (1.0-4.0) 0.46
Neopterin, nmol/L 7.7 (6.4-9.2) 8.0 (6.6-10.0) 8.3 (6.8-10.6) 8.8 (6.9-11.8) <0.001
Serum lipids and lipoproteins  
Total cholesterol, mmol/L 4.9 (4.3-5.8) 5.0 (4.3-5.8) 4.9 (4.2-5.7) 4.8 (4.2-5.7) 0.01
LDL-C, mmol/L 2.9 (2.4-3.6) 3.0 (2.4-3.8) 2.9 (2.4-3.7) 2.9 (2.3-3.7) 0.39
HDL-C, mmol/L 1.3 (1.1-1.6) 1.2 (1.0-1.5) 1.2 (1.0-1.4) 1.2 (1.0-1.4) <0.001
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ApoB100, g/L 0.8 (0.7-1.0) 0.9 (0.7-1.1) 0.9 (0.7-1.1) 0.9 (0.7-1.1) 0.07
Apo A1, g/L 1.3 (1.2-1.5) 1.3 (1.1-1.5) 1.3 (1.1-1.5) 1.3 (1.1-1.4) <0.001
Prior CVD, n (%)  
AMI 323 (31.8) 406 (40.1) 442 (41.5) 474 (47.2) <0.001
PAD 66 (6.5) 82 (8.1) 106 (9.9) 115 (11.5) <0.001
PCI 153 (15.1) 190 (18.8) 216 (20.3) 224 (22.3) <0.001
CABG 87 (8.6) 105 (10.4) 123 (11.5) 157 (15.6) <0.001
LVEF (%) 68 (60-70) 66 (60-70) 66 (60-70) 65 (58-70) <0.001
Medications before angiography, n (%)
Aspirin 818 (80.6) 805 (79.5) 858 (80.5) 803 (80.1) 0.89
Statins 731 (72.0) 708 (69.9) 799 (75.0) 728 (72.5) 0.29
CCB 206 (20.3) 209 (20.6) 224 (21.0) 269 (26.8) 0.001
β-Blocker 727 (71.6) 736 (72.7) 795 (74.6) 747 (74.4) 0.09
ACEI 150 (14.8) 184 (18.2) 218 (20.5) 265 (26.4) <0.001
Medications after angiography, n (%)
Aspirin 804 (79.2) 819 (80.8) 876 (82.2) 837 (83.4) 0.01
Statins 783 (77.1) 804 (79.4) 877 (82.3) 815 (81.2) 0.01
CCB 207 (20.4) 209 (20.6) 231 (21.7) 276 (27.5) <0.001
β-Blocker 703 (69.3) 723 (71.4) 788 (73.9) 752 (74.9) 0.002
ACEI 159 (15.7) 192 (19.0) 223 (20.9) 268 (26.7) <0.001
Plasma riboflavin, nmol/L 10.9 (7.4-17.3) 11.2 (7.7-18.8) 10.9 (7.2-17.1) 11.9 (7.8-19.4) 0.02
Serum γBB, µmol/L 0.9 (0.8-1.0) 1.0 (0.9-1.1) 1.1 (0.9-1.2) 1.2 (1.0-1.3) <0.001
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Plasma TMAO, µmol/L 4.1 (2.8-6.1) 5.1 (3.4-7.9) 6.0 (4.0-9.7) 9.3 (5.7-17.9) <0.001
Continuous variables are presented as medians (25th-75th percentiles), and categorical variables are reported as counts (%). ACEIs indicates angiotensin-
converting enzyme inhibitors; AMI, acute myocardial infarction; apoA1, apolipoprotein A1; apoB100, apolipoprotein B100; BMI, body mass index; CABG, 
coronary artery bypass grafting; CCB, calcium channel blockers; CVD, cardiovascular disease; CRP, C-reactive protein; γBB, gamma-butyrobetaine; eGFR, 
estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection 
fraction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TMAO, trimethylamine-N-oxide; TML, trimethyllysine.
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Table 2. Spearman correlation coefficients between plasma TML, downstream carnitine 
metabolites and TMAO 
 TML γBB Carnitine TMAO
TML * 0.41 0.21 0.41
γBB 0.41 * 0.44 0.23
Carnitine 0.21 0.44 * 0.08
TMAO 0.41 0.23 0.08 *
TML indicates trimethyllysine; TMAO, trimethylamine-N-oxide; γBB, gamma-butyrobetaine.
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Table 3. Risk association between plasma trimethyllysine and acute myocardial infarction
Unadjusted Model 1* Model 2†
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Plasma TML
Quartiles
1st Reference Reference Reference
2nd 1.46 (1.02-2.09) 0.04 1.32 (0.91-1.90) 0.14 1.25 (0.87-1.81) 0.24
3rd 1.72 (1.21-2.43) 0.003 1.45 (1.01-2.08) 0.04 1.34 (0.93-1.94) 0.11
4th 2.73 (1.97-3.79) <0.001 2.19 (1.56-3.09) <0.001 1.79 (1.23-2.59) 0.002
Trend 1.38 (1.25-1.53) <0.001 1.29 (1.16-1.44) <0.001 1.20 (1.07-1.35) 0.002
Per 1-SD‡ 1.34 (1.22-1.46) <0.001 1.28 (1.16-1.41) <0.001 1.15 (1.03-1.29) 0.01
CI indicates confidence interval; HR, hazard ratio; SD, standard deviation; TML, trimethyllysine.
*Model 1: Adjusted for age and sex.
†Model 2: Adjusted for age, sex, diabetes mellitus, smoking, hypertension, estimated glomerular filtration rate, apolipoprotein A1 and apolipoprotein B100.
‡Log-transformed.
Table 4. Risk association between plasma trimethylamine-N-oxide and acute myocardial infarction
Unadjusted   Model 1*  Model 2†
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Quartiles
1st Reference Reference Reference
2nd 1.14 (0.85-1.63) 0.43 0.98 (0.70-1.36) 0.89 0.88 (0.63-1.23) 0.47
3rd 1.38 (1.00-1.89) 0.048 1.08 (0.78-1.49) 0.64 0.94 (0.68-1.31) 0.73
4th 1.50 (1.10-2.05) 0.010 1.07 (0.77-1.47) 0.69 0.81 (0.58-1.14) 0.22
Trend 1.15 (1.05-1.27) 0.004 1.03 (0.93-1.14) 0.56 0.95 (0.85-1.05) 0.30
Per 1-SD‡ 1.21 (1.09-1.34) <0.001  1.09 (0.98-1.21) 0.12  0.97 (0.87-1.10) 0.70
CI indicates confidence interval; HR, hazard ratio; SD, standard deviation; TMAO, trimethylamine-N-oxide.
*Model 1: Adjusted for age and sex.
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Table 5. Risk association between plasma TML and acute myocardial infarction according to 
subgroups of traditional cardiovascular risk factors, riboflavin, and TMAO
Subgroups HR (95% CI)* P-value Pint
Age
≤median 1.12 (0.95-1.31) 0.19 0.06
>median 1.37 (1.22-1.55) <0.001
Sex
Female 1.35 (1.11-1.65) 0.003 0.52
Male 1.27 (1.14-1.41) <0.001
Diabetes
No 1.24 (1.11-1.39) <0.001 0.61
Yes 1.31 (1.11-1.54) 0.001
Hypertension
No 1.36 (1.07-1.57) <0.001 0.23
Yes 1.21 (1.07-1.37) 0.003
Smoking
No 1.27 (1.11-1.44) <0.001 0.89
Yes 1.29 (1.12-1.49) <0.001
ApoA1
≤median 1.27 (1.13-1.44) <0.001 0.95
>median 1.28 (1.09-1.49) 0.001
ApoB100
≤median 1.29 (1.12-1.48) 0.001 0.58
>median 1.26 (1.11-1.43) <0.001
eGFR
≤median 1.34 (1.19-1.49) <0.001 0.21
>median 1.12 (0.93-1.36) 0.23
Riboflavin
≤median 1.12 (0.96-1.32) 0.15 0.035
>median 1.38 (1.23-1.56) <0.001
TMAO
≤median 1.41 (1.16-1.71) <0.001 0.35
>median 1.26 (1.11-1.41) <0.001
AMI indicates acute myocardial infarction; ApoA1, apolipoprotein A1; ApoB100, apolipoprotein 
B100; γBB: gamma-butyrobetaine; eGFR, estimated glomerular filtration rate; HR, hazard ratio; SD, 
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Figure 1. Kaplan–Meier curve showing crude event-free survival according to quartiles of plasma 
TML. The x-axis is trimmed at 6.5 years. AMI indicates acute myocardial infarction; TML, 
trimethyllysine.
*Per 1SD (log transformed). Adjusted for age and sex.
A
cc
ep
te
d 
A
rt
ic
le
